Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study - Top-Institutions - MDSpire

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • By

  • Lilan Zhao

  • Tianxing Guo

  • Yi Zhang

  • Zhen Huang

  • Yangyun Huang

  • Lihuan Zhu

  • Xing Chen

  • Nan Zhang

  • Liren Guo

  • Rongzhi Huang

  • Guojun Geng

  • Ning Li

  • Shuxing Chen

  • Xiaojie Pan

  • Wenshu Chen

  • October 24, 2025

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Clinical Trials

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Antiangiogenic Therapy

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Clinical Research

  • #4

    Fudan University Shanghai Cancer Center
    Fudan University Shanghai Cancer Center

    Shanghai, China

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Antiangiogenic Therapy

  • #5

    Peking University Cancer Hospital & Institute
    Peking University Cancer Hospital & Institute

    Beijing, China

    Key Differentiators

    • Thoracic Oncology
    • Immunotherapy
    • Clinical Trials

Original Source(s)

Assessment of the safety and effectiveness of neoadjuvant camrelizumab and apatinib in conjunction with chemotherapy for stage IIIA (N2) non-small cell lung cancer: Results from a multi-center, single-arm phase II study

  • by Lilan Zhao, Tianxing Guo, Yi Zhang, Zhen Huang, Yangyun Huang, Lihuan Zhu, Xing Chen, Nan Zhang, Liren Guo, Rongzhi Huang, Guojun Geng, Ning Li, Shuxing Chen, Xiaojie Pan, Wenshu Chen

  • October 24, 2025

Related Content

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate